Lymphoproliferative disorders of natural killer cells: report of two cases and review of literature.

Jing Zheng, Hongjiang Liu, Yonghong Chen, Wei Xie, Kai Wang, Lu Chen, Kaibo Gao

Open access · greenAbstract readCase Reports

In one paragraph

Article in International journal of clinical and experimental pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact, top 87% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jing ZhengDepartment of Hematology, The First People's Hospital of Yichang, China Three Gorges University Yichang, Hubei, China.

Hongjiang LiuDepartment of Rheumatology and Clinical Immunology, The First People's Hospital of Yichang, China Three Gorges University Yichang, Hubei, China.

Yonghong ChenDepartment of Hematology, The First People's Hospital of Yichang, China Three Gorges University Yichang, Hubei, China.

Wei XieDepartment of Hematology, The First People's Hospital of Yichang, China Three Gorges University Yichang, Hubei, China.

Kai WangDepartment of Rheumatology and Clinical Immunology, The First People's Hospital of Yichang, China Three Gorges University Yichang, Hubei, China.

Lu ChenDepartment of Medical Record Management Division, The First People's Hospital of Yichang, China Three Gorges University Yichang, Hubei, China.

Kaibo GaoDepartment of Hematology, The First People's Hospital of Yichang, China Three Gorges University Yichang, Hubei, China.

China Three Gorges University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lymphoproliferative disorders of natural killer cells (LPD-NK) are rare lymphoproliferative diseases involving NK cells. Here, we present two cases of LPD-NK. The first case is a 63-year-old man who presented with high fever, cytopenia, and a history of myelodsyplastic syndrome. He was finally diagnosed with aggressive NK cell leukemia and died due to progression of the disease within 15 days of diagnosis. The second case is a 70-year-old man with granulocytopenia who did not have clinical manifestations; he was diagnosed with chronic lymphoproliferative disorder of NK cells and a watch and wait approach was adopted until six-month follow up. This article describes the clinical features, pathogenesis, diagnosis, treatments, and prognosis of LPD-NK through a literature review of case reports.

Indexed as

aggressive natural killer cell leukemiachronic lymphoproliferative disorder of natural killer cellsdiagnosisLymphoproliferative disorder of natural killer cellstherapy

Identifiers

PMID32782701

PMCPMC7414496

OpenAlexW3049545875

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.